Certara corrects misstatement on 2025 adjusted EBITDA for divested regulatory, medical writing unit

PUBT · 2d ago
Certara corrects misstatement on 2025 adjusted EBITDA for divested regulatory, medical writing unit
  • Certara corrected a misstatement from its Aug. 4, 2026 Q2 earnings call on 2025 adjusted EBITDA from its divested Regulatory and Medical Writing unit.
  • The call incorrectly cited about $17 million adjusted EBITDA excluding unallocated overhead; the $17 million figure includes unallocated overhead.
  • Adjusted EBITDA excluding unallocated corporate expense that remains with the company was about $23 million.
  • An updated earnings presentation replaced the version that carried the same error.
  • The clarification does not change previously reported results or the 2026 financial outlook.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Certara Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-092730), on August 07, 2026, and is solely responsible for the information contained therein.